Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Single-center series of boys with recurrent strokes and rotational vertebral arteriopathy.

  • Read more about Single-center series of boys with recurrent strokes and rotational vertebral arteriopathy.

Pediatric Multiple Sclerosis Severity Score in a large US cohort.

  • Read more about Pediatric Multiple Sclerosis Severity Score in a large US cohort.

Spectrum of cerebral arteriopathies in children with arterial ischemic stroke.

  • Read more about Spectrum of cerebral arteriopathies in children with arterial ischemic stroke.

Quantifying “Clinically Meaningful Changes” in Seizure Frequency - Data from Three Phase 3 Studies of ZX008 (Fenfluramine Hydrochloride Oral Solution) in Dravet Syndrome: Do Expectations and Views Change Over Time? (2247).

  • Read more about Quantifying “Clinically Meaningful Changes” in Seizure Frequency - Data from Three Phase 3 Studies of ZX008 (Fenfluramine Hydrochloride Oral Solution) in Dravet Syndrome: Do Expectations and Views Change Over Time? (2247).

Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open-Label Extension Study (4684).

  • Read more about Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open-Label Extension Study (4684).

Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?

  • Read more about Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?

Predicting developmental outcomes in preterm infants: A simple white matter injury imaging rule.

  • Read more about Predicting developmental outcomes in preterm infants: A simple white matter injury imaging rule.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

  • Read more about Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

  • Read more about Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I.

  • Read more about Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I.

Pagination

  • Previous page ‹‹
  • Page 4
  • Next page ››
Subscribe to Neurology

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List